Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Carolina Actimmune Prior Auth | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTIMMUNE (S) Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Actimmune injection under the South Carolina Medicare Advantage Prescription Drug plan. Coverage is based on chronic granulomatous disease or severe malignant osteopetrosis, with continuation of prior therapy eligible for approval.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTIMMUNE (S) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming a diagnosis of chronic granulomatous disease or severe malignant osteopetrosis.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered diagnostic indications
    12 monthsCoverage duration
    Not requiredPrerequisite Part D drug
    100 mcg/0.5 mLAffected injection strength

    Covered Products and Medical Necessity

    Qualifying Indications and Product-Specific Coverage

    Covered when the applicable diagnosis-specific criteria are met.

    Actimmune: Chronic granulomatous disease or severe malignant osteopetrosis.
    Alyq: Symptomatic PAH confirmed by right-heart catheterization or current PAH therapy; initial prescribing by or in consultation with a pulmonologist or cardiologist. Reauthorization requires positive clinical response.
    Adempas: Symptomatic PAH confirmed by right-heart catheterization or current PAH therapy; or symptomatic inoperable/persistent/recurrent CTEPH or current PAH therapy. Initial prescribing by or in consultation with a pulmonologist or cardiologist; reauthorization requires positive clinical response.
    Afinitor: SEGA associated with TSC requiring intervention; advanced RCC after SUTENT or NEXAVAR failure, contraindication, or intolerance; progressive unresectable, locally advanced, or metastatic pNET; renal angiomyolipoma with TSC; advanced HR-positive/HER2-negative breast cancer after FEMARA or ARIMIDEX failure, contraindication, or intolerance; or progressive, well-differentiated, nonfunctional unresectable, locally advanced, or metastatic GI/lung NET. SEGA requires age at least 1 year.

    Initial Authorization Criteria

    Initial Authorization Criteria

    Initial authorization requires the following criteria.

    Actimmune: CGD or SMO.
    Alyq: Symptomatic PAH confirmed by right-heart catheterization or current PAH therapy; pulmonologist/cardiologist involvement.
    Adempas: Qualifying symptomatic PAH or symptomatic inoperable/persistent/recurrent CTEPH, or current PAH therapy; pulmonologist/cardiologist involvement.
    Afinitor/Afinitor Disperz: Qualifying SEGA/TSC, oncology, renal angiomyolipoma, NET, seizure, or breast-cancer pathway with applicable age and prior-therapy requirements.

    Reauthorization and Continuation Criteria

    Continuation Criteria

    Continuation or reauthorization may be approved when the following criteria are met.

    Actimmune/Afinitor/Afinitor Disperz/Akeega/Alecensa: Continuation of prior therapy is requested.
    Alyq/Adempas: Positive clinical response to therapy.
    Aimovig: Positive response and decreased use of acute migraine medications; continue monitoring medication-overuse headache when applicable and avoid CGRP combination.
    Prolastin-c: Positive clinical response and continued conventional emphysema treatment.

    Prerequisite and Step-Therapy Requirements

    ProductRequired prior therapyDuration or qualifying conditions
    AfinitorPrerequisite Part D drug; for renal cell carcinoma, SUTENT (sunitinib) or NEXAVAR (sorafenib); for hormone receptor-positive, HER2-negative breast cancer, FEMARA (letrozole) or ARIMIDEX (anastrozole).Trial and failure, contraindication, or intolerance to the indication-specific therapy. The prerequisite Part D drug requirement applies under the policy.
    Avtozma — rheumatoid arthritisTwo specified therapies: Enbrel (etanercept), one formulary adalimumab product, Orencia (abatacept), Rinvoq (upadacitinib), or Xeljanz/Xeljanz XR (tofacitinib).Trial and failure, contraindication, or intolerance to two therapies, or an attestation that a trial may be inappropriate.
    Avtozma — systemic juvenile idiopathic arthritisOne NSAID, such as ibuprofen or naproxen.At least a 1-month trial at the maximally tolerated dose.
    Avtozma — polyarticular juvenile idiopathic arthritisTwo specified therapies: Enbrel (etanercept), one formulary adalimumab product, Orencia (abatacept), Rinvoq/LQ, or Xeljanz (tofacitinib).Trial and failure, contraindication, or intolerance to two therapies, or an attestation that a trial may be inappropriate.
    BraftoviErbitux (cetuximab), plus either prior therapy or fluorouracil-based chemotherapy.Braftovi must be used with Erbitux and either follow prior therapy or be combined with fluorouracil-based chemotherapy.
    CabometyxIndication-specific prior therapy: Nexavar for HCC; prior VEGFR-targeted therapy for DTC; or prior treatment for well-differentiated neuroendocrine tumors.Trial and failure, contraindication, or intolerance to Nexavar for HCC; progression after prior VEGFR-targeted therapy for DTC; or previous treatment for neuroendocrine tumors.
    Caplyta — schizophreniaTwo specified oral generic formulary atypical antipsychotics: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine IR/ER, risperidone, or ziprasidone.Trial and failure, contraindication, or intolerance to two agents.
    ChenodalUrsodiol.Trial and failure, contraindication, or intolerance to ursodiol.
    Ciclopirox Nail LacquerOral terbinafine.Trial and failure, contraindication, or intolerance; minimum 6-week supply for fingernail disease or 12-week supply for toenail disease.
    CobenfyTwo oral generic formulary atypical antipsychotics: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, or ziprasidone.Intolerance to two agents is required.
    CopiktraAt least two prior therapies for CLL/SLL, such as chlorambucil, obinutuzumab, ofatumumab, bendamustine, ibrutinib, or rituximab.Trial and failure, contraindication, or intolerance to at least two prior therapies; disease must be relapsed or refractory.

    Clinical Thresholds and Measurement Requirements

    Key thresholds and restrictions
    Episodic migraineAt least 4 migraine days per month
    Chronic migraineAt least 8 migraine days per month
    Pre-treatment serum AATLess than 11 µM/L; equivalent to less than 80 mg/dL by radial immunodiffusion or less than 57 mg/dL by nephelometry
    Plaque psoriasis severityAt least 3% body surface area involvement, or severe scalp, palmoplantar, facial, or genital involvement
    Cosentyx treatment trials4-week topical therapy trial; 1-month NSAID trial
    Cyclobenzaprine age restrictionPrior authorization applies at age 65 years or older
    Roflumilast prior COPD therapy

    Authorization Duration and Quantity Limits

    Product-specific authorization durations
    Braftovi12-month coverage duration
    Briviact, Brukinsa, Cabometyx, Calquence, Caplyta, and Caprelsa12-month coverage duration
    Bronchitol6 months for initial coverage; 12 months for reauthorization
    Cablivi3-month coverage duration
    Emgality6 months for initial episodic or chronic migraine; 3 months for initial episodic cluster headache; 12 months for reauthorization
    Empaveli, Ensacove, Epidiolex, Gomekli, Genotropin, Genotropin Miniquick, and Hernexeos12-month coverage duration
    Enbrel, Epclusa Preferred, Glycopyrrolate, and Humira

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Actimmune Through Prolastin-c: PA and Supporting Documentation

    Prior authorization is required for the products below. Submit the diagnosis, disease severity, relevant laboratory, genetic or biomarker results, prior-treatment history, prescriber specialty, combination therapy, and continuation-response information applicable to the requested indication.

    • Alyq: PAH diagnosis; symptomatic disease; confirmation by right-heart catheterization or current PAH therapy; initial prescribing by or consultation with a pulmonologist or cardiologist; document positive response for reauthorization.
    • Adempas: symptomatic PAH confirmed by right-heart catheterization or current PAH therapy, or symptomatic inoperable/persistent/recurrent CTEPH; pulmonologist/cardiologist involvement; document positive response at reauthorization.
    • Afinitor: document the indication—SEGA associated with TSC, advanced RCC, progressive unresectable/locally advanced/metastatic pNET or GI/lung NET, TSC-associated renal angiomyolipoma, or advanced HR-positive/HER2-negative breast cancer—and required prior therapy such as sunitinib, sorafenib, letrozole, or anastrozole. Continuation of prior therapy is approvable.
    • Afinitor Disperz: document SEGA requiring intervention or TSC-associated partial-onset seizures, including age requirements and neurologist involvement for seizures.
    • Aimovig: document episodic migraine with at least 4 migraine days/month or chronic migraine with at least 8 migraine days/month, consideration of medication-overuse headache, age 18 or older, and continuation response; it may not be combined with another preventive CGRP inhibitor.

    Policy Terms and Abbreviations

    Clinical abbreviations and definitions
    Chronic granulomatous disease (CGD)A rare inherited disorder characterized in this policy by the abbreviation CGD
    Severe malignant osteopetrosis (SMO)A severe form of osteopetrosis identified in this policy by the abbreviation SMO
    CTEPHChronic thromboembolic pulmonary hypertension
    SEGA associated with TSCSubependymal giant cell astrocytoma associated with tuberous sclerosis complex
    EM and CMEM: episodic migraine, requiring at least 4 migraine days per month; CM: chronic migraine, requiring at least 8 migraine days per month
    AAT deficiencyAlpha-1 antitrypsin deficiency
    SSc-ILD and idiopathic interstitial pneumonia pattern

    Policy Scope and Clinical Context

    This pharmacy prior authorization policy window addresses a broad set of specialty-drug categories, including pulmonary hypertension therapies, oncology and targeted antineoplastic agents, tuberous-sclerosis and mTOR therapies, migraine-prevention products, alpha-1 antitrypsin replacement, hematology and rare-disease therapies, anticonvulsants, cystic-fibrosis treatments, antifungals, metabolic therapies, biologics, growth hormone, and neurologic therapies.

    The clinical scope is indication-specific. Initial requests generally require documentation of the covered diagnosis and any applicable disease severity, laboratory or biomarker findings, prior-treatment requirements, specialist involvement, or treatment combinations. Reauthorization may allow continuation of prior therapy or require documented positive clinical response, depending on the product and indication.

    Administration Setting

    Billing Rule

    Document office administration of the first dose

    The first Cablivi dose must be administered in the office by a healthcare provider as a bolus intravenous injection. Submit documentation of the administration or planned administration with the request.

    • Office administration is required for the first dose.
    • Administration must be by a healthcare provider.
    • Route and method: bolus intravenous injection.
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTIMMUNE (S) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming a diagnosis of chronic granulomatous disease or severe malignant osteopetrosis.
    SourceLink
    On This Page
    Covered Products and Medical NecessityInitial Authorization CriteriaReauthorization and Continuation CriteriaPrerequisite and Step-Therapy RequirementsClinical Thresholds and Measurement RequirementsAuthorization Duration and Quantity LimitsPrior Authorization, Documentation, and Denial RisksPolicy Terms and AbbreviationsPolicy Scope and Clinical ContextAdministration Setting
    Afinitor Disperz: SEGA associated with TSC requiring intervention in a patient at least 1 year old; or TSC-associated partial-onset seizures in a patient at least 2 years old. Seizure treatment requires neurologist prescribing or consultation.
    Aimovig: Episodic migraine with at least 4 migraine days per month; or chronic migraine with medication-overuse headache considered and offending medication discontinued, plus at least 8 migraine days per month. Initial treatment requires age at least 18 years; do not combine with another CGRP inhibitor.
    Akeega: Metastatic prostate cancer with a deleterious or suspected deleterious BRCA mutation, used with prednisone and GnRH therapy.
    Alecensa: Non-small cell lung cancer.
    Prolastin-c: Congenital AAT deficiency with emphysema, continued conventional emphysema treatment, and qualifying PiZZ, PiZ(null), Pi(null)(null), or other rare genotype with pretreatment serum AAT below 11 µM/L.Serum AAT <11 µM/L

    Avtozma Indication-Specific Criteria

    Avtozma is covered when the indication-specific diagnosis, prerequisite requirements, and prescriber criteria are met.

    Rheumatoid arthritis: Moderately to severely active RA and either failure, contraindication, or intolerance to two specified therapies (Enbrel, a formulary adalimumab product, Orencia, Rinvoq, or Xeljanz/Xeljanz XR), an attestation that a trial may be inappropriate, or continuation of prior therapy.
    Giant cell arteritis: Diagnosis of giant cell arteritis.
    Systemic juvenile idiopathic arthritis: Active SJIA and a minimum one-month trial of an NSAID such as ibuprofen or naproxen at the maximally tolerated dose.At least 1 month
    Polyarticular juvenile idiopathic arthritis: Active PJIA and either failure, contraindication, or intolerance to two specified therapies (Enbrel, a formulary adalimumab product, Orencia, Rinvoq/LQ, or Xeljanz), an attestation that a trial may be inappropriate, or continuation of prior therapy.
    SSc-ILD with exclusion of other known causes of ILD and either HRCT showing an idiopathic interstitial pneumonia pattern revealing SSc-ILD/probable SSc-ILD without biopsy, or concordant HRCT and surgical lung-biopsy findings.
    Continuation: Reauthorization requires positive response: reduced active swollen/tender joints or improved symptoms for RA/PJIA; reduced active joints or improved clinical features for SJIA; and positive clinical response for GCA or SSc-ILD.

    Braftovi Through Cayston Criteria

    Coverage requires the applicable product-specific pathway.

    Braftovi: Metastatic BRAF V600E-mutant NSCLC confirmed by an FDA-approved or CLIA-approved test and used with Mektovi; or the listed Erbitux combination indication with prior therapy or fluorouracil-based chemotherapy.
    Briviact: Partial-onset seizures; age at least 1 month.Age >=1 month
    Bronchitol: Cystic fibrosis, passed Bronchitol Tolerance Test, and pulmonologist or specialist prescribing/consultation. Reauthorization requires positive clinical response.
    Brukinsa: MCL after at least one prior therapy; WM/LPL; relapsed/refractory MZL after at least one anti-CD20 regimen; CLL/SLL with contraindication or intolerance to Calquence; or relapsed/refractory FL used with Gazyva after at least two prior systemic lines.
    Cablivi: aTTP; first dose administered by a healthcare provider as an IV bolus; immunosuppressive therapy; and plasma exchange or completion of plasma exchange fewer than 59 days earlier.
    Cabometyx: RCC; HCC after Nexavar failure/intolerance; DTC after VEGFR-targeted therapy with radioactive-iodine refractory/ineligible disease; or previously treated unresectable, locally advanced, metastatic, well-differentiated pNET/epNET. DTC requires age at least 12 years.
    Calquence: Treatment-naive MCL ineligible for autologous HSCT and used with bendamustine/rituximab; MCL after at least one prior therapy; or CLL/SLL.
    Caplyta: Schizophrenia after two specified generic atypical-antipsychotic trials or intolerance; bipolar depression as monotherapy or adjunctive lithium/valproate after quetiapine or olanzapine; or adjunctive MDD after aripiprazole and quetiapine IR/ER.
    Caprelsa: Metastatic or unresectable locally advanced MTC that is symptomatic or progressive.
    Cayston: Evidence of Pseudomonas aeruginosa in the lungs; for cystic fibrosis, age at least 7 years. Reauthorization requires benefit such as fewer pulmonary exacerbations.CF age >=7 years

    Cerdelga Through Metyrosine Criteria

    Coverage is available for the following indication-specific pathways and restrictions.

    Cerdelga: Gaucher disease type 1; age at least 18 years; extensive, intermediate, or poor CYP2D6 metabolizer status by an FDA-cleared test.
    Chenodal: Radiolucent gallstones, well-opacifying gallbladder, not a surgical candidate, noncalcified/non-radiopaque stones, and ursodiol failure, contraindication, or intolerance; gastroenterologist prescribing or consultation.
    Cholbam: Single-enzyme-defect bile-acid synthesis disorder confirmed by urinary mass-spectrometry or molecular testing; or qualifying peroxisomal disorder with liver disease, steatorrhea, or fat-soluble-vitamin complications, used adjunctively.
    Cialis: Contraindication or intolerance to an alpha-blocker or 5-alpha reductase inhibitor and no concurrent nitrate use.
    Ciclopirox: No lunula/matrix involvement; confirmed fingernail or toenail onychomycosis; qualifying nail severity; and oral terbinafine failure, contraindication, or intolerance (minimum 6 weeks for fingernail or 12 weeks for toenail disease).
    Cinryze: Confirmed HAE, prophylaxis against HAE attacks, age at least 6 years, specialist involvement, and no combination with another approved HAE prophylaxis.
    Cobenfy: Intolerance to two listed oral generic formulary atypical antipsychotics.
    Cometriq: Metastatic medullary thyroid cancer.
    Copiktra: CLL/SLL that is relapsed or refractory and failure, contraindication, or intolerance to at least two prior therapies.At least 2 prior therapies
    Cosentyx: Indication-specific plaque psoriasis, PsA, AS, nr-axSpA, ERA, or moderate-to-severe HS criteria, including required topical or NSAID trials where applicable and specialist involvement.
    Cosentyx IV: Active PsA, AS, or nr-axSpA with failure, contraindication, or intolerance to the required alternatives, or continuation of prior therapy; specialist involvement required.
    Cotellic: Unresectable/metastatic BRAF V600E/V600K-mutated melanoma used with Zelboraf, or histiocytic neoplasm.
    Cresemba: Invasive aspergillosis or invasive mucormycosis.
    Ctexli: Cerebrotendinous xanthomatosis confirmed by pathogenic CYP27A1 variant testing and prescribed by or in consultation with a neurologist, geneticist, metabolic disease specialist, or endocrinologist.
    Cyclobenzaprine: Acute painful musculoskeletal muscle spasm; fibromyalgia-related symptoms; or acute temporomandibular disorder with lower-jaw muscle tenderness and NSAID use. PA applies at age 65 years or older.
    Roflumilast: COPD with qualifying exacerbations and failure, intolerance, or contraindication to two prior COPD therapies.
    Danziten: Philadelphia chromosome-positive CML.
    Pyrimethamine: Active, secondary-prophylaxis, or congenital toxoplasmosis; or primary prophylaxis after TMP-SMX intolerance plus failed desensitization or prior life-threatening reaction. Malaria treatment/prophylaxis is excluded.
    Daurismo: Newly diagnosed AML, used with low-dose cytarabine, and age at least 75 years or comorbidities precluding the alternative treatment.
    Deferasirox: Transfusional iron overload with ferritin >1,000 mcg/L and at least 100 mL/kg packed RBCs; MDS with qualifying risk and >20 RBC transfusions; or NTDT with LIC at least 5 mg Fe/g dry weight and the required ferritin level.
    Metyrosine: Biochemically confirmed pheochromocytoma for preoperative preparation after both alpha- and beta-blocker failure/contraindication/intolerance; or hormonally active disease requiring nonsurgical or malignant-disease treatment with failure to reach normotension after alpha-1 and beta blockade. Essential hypertension use is excluded.

    Emgality Through Fotivda Criteria

    Coverage requires the applicable product-specific diagnosis and treatment pathway.

    Emgality: Episodic migraine with at least 4 migraine days/month; chronic migraine with at least 8 migraine days/month and medication-overuse headache addressed; or episodic cluster headache with at least two qualifying cluster periods. Age at least 18 years and no prohibited CGRP combination.
    Empaveli: PNH; or C3G/primary IC-MPGN with proteinuria-reduction objective, no kidney transplant for primary IC-MPGN, and maximally tolerated ACE inhibitor, ARB, or SGLT2 therapy for at least 12 weeks.
    Enbrel: RA, PJIA, PsA, plaque psoriasis, or AS meeting diagnosis, severity, prior-therapy, and specialist criteria.
    Endari: Sickle cell disease with at least two painful crises in the prior 12 months.>=2 crises/12 months
    Ensacove: Locally advanced or metastatic ALK-rearrangement-positive NSCLC confirmed by approved testing, with no prior ALK inhibitor.
    Epclusa Preferred: Chronic hepatitis C treated according to current AASLD/IDSA guidance and not combined with another HCV direct-acting antiviral.
    Epidiolex: Seizures associated with LGS, Dravet syndrome, or TSC; age at least 1 year; neurologist involvement. LGS additionally requires two formulary anticonvulsant trials, contraindications, or intolerances.
    Procrit: Qualifying anemia associated with CKD, chemotherapy, preoperative transfusion reduction, HCV treatment, HIV, or MDS with the applicable laboratory, treatment, and iron-store criteria.
    Erivedge: Metastatic BCC, or locally advanced BCC recurring after surgery or not amenable to surgery.
    Erleada: Prostate cancer.
    Pirfenidone: IPF established by excluding other ILD causes and meeting the applicable HRCT/biopsy findings; pulmonologist involvement required.
    Eucrisa: Mild-to-moderate atopic dermatitis and topical corticosteroid failure, contraindication, or intolerance, unless the affected site is sensitive.
    Evrysdi: SMA type I, II, or III with qualifying SMN1/chromosome 5q findings, at least two SMN2 copies, required respiratory status, baseline motor assessment, no chronic SMN-modifying combination, and applicable gene-therapy history.
    Fabrazyme: Fabry disease confirmed by pathogenic GLA mutation, deficient alpha-galactosidase A activity, or significant clinical manifestations; age at least 2 years and no combination Fabry therapy.
    Fasenra: Severe eosinophilic asthma with eosinophils at least 150 cells/µL and qualifying exacerbations/hospitalization plus controller therapy; EGPA with corticosteroid therapy; or HES with secondary causes excluded, FIP1L1-PDGFRA-negative status, eosinophils at least 1000 cells/µL, and prior therapy.
    Fentanyl citrate oral transmucosal: Breakthrough cancer pain, around-the-clock long-acting opioid use, and at least one week of qualifying opioid tolerance; specialist involvement required.
    Fintepla: Seizures associated with Dravet syndrome or LGS, age at least 2 years, and neurologist prescribing or consultation.
    Icatibant: Confirmed HAE, treatment of an acute attack, age at least 18 years for initial therapy, immunologist/allergist involvement, and no combination with another approved acute HAE treatment.
    Firdapse: LEMS, age at least 6 years, and neurologist prescribing or consultation.
    Firmagon: Advanced or metastatic prostate cancer.
    Fotivda: Advanced relapsed/refractory RCC after at least two prior systemic therapies.At least 2 prior systemic therapies

    Glycopyrrolate Through Increlex Criteria

    Coverage requires the applicable diagnosis-specific pathway.

    Glycopyrrolate: Peptic ulcer plus concomitant PPI therapy, or PPI contraindication/intolerance plus H2-receptor antagonist therapy. Reauthorization requires persistent/new ulcer and reduced symptoms.
    Gomekli: Neurofibromatosis type 1 with inoperable plexiform neurofibromas.
    Preferred growth hormone products: Applicable criteria for pediatric or adult GH deficiency, PWS, SGA growth failure, Turner, Noonan, SHOX deficiency, chronic renal insufficiency-related growth failure, adult idiopathic GH deficiency, or idiopathic short stature.
    Hernexeos: Unresectable or metastatic non-squamous NSCLC with an activating HER2/ERBB2 tyrosine-kinase-domain mutation confirmed by approved testing.
    Humira: Applicable criteria for RA, PJIA, PsA, plaque psoriasis, AS, Crohn disease, uveitis, UC, or HS, including required severity and prior-therapy criteria.
    Hyrnuo: Locally advanced or metastatic non-squamous NSCLC with activating HER2/ERBB2 mutation confirmed by approved testing and prior systemic therapy.
    Ibrance: Breast cancer.
    Ibtrozi: Locally advanced or metastatic NSCLC with ROS1 rearrangement-positive tumor confirmed by approved testing.
    Iclusig: CML or Ph-positive ALL; Ph-positive ALL requires chemotherapy up to 20 cycles or qualifying monotherapy use.
    Idhifa: Relapsed/refractory AML with IDH2 mutation confirmed by approved testing.
    Igalmi: Schizophrenia or bipolar I/II disorder with acute agitation, failure/contraindication/intolerance to at least two acute-agitation products, and current maintenance therapy.
    Imbruvica: CLL, WM/LPL, SLL, or cGVHD; cGVHD requires failure of at least one systemic-therapy line.
    Imkeldi: Eligible Ph-positive CML/ALL, MDS/MPD, ASM, HES/CEL, DFSP, or GIST and inability to swallow generic imatinib tablets because of age, impairment, dysphagia, or feeding/nasogastric tube use.
    Inbrija: Parkinson disease with intermittent OFF episodes, current carbidopa/levodopa, failure/contraindication/intolerance to two adjunctive therapy classes, and neurologist involvement.
    Increlex: Severe primary IGF-1 deficiency with height and basal IGF-1 SDS at or below -3.0 and normal/elevated GH; or GH gene deletion with neutralizing antibodies.Height SDS <=-3.0; basal IGF-1 SDS <=-3.0

    Coverage is not available when the requested therapy violates a product-specific safety or combination restriction. Aimovig and Emgality must not be used with another CGRP inhibitor for preventive migraine treatment; Emgality for episodic cluster headache must not be combined with another injectable CGRP inhibitor. Cialis is excluded with concurrent nitrate use, and Ciclopirox is not supported when lunula or matrix involvement is present. Cinryze must not be combined with another approved HAE prophylaxis treatment, and icatibant must not be combined with another approved treatment for an acute HAE attack.

    Pyrimethamine requests for malaria treatment or prophylaxis are not authorized. Metyrosine is not covered when used to control essential hypertension. Empaveli is not covered for primary IC-MPGN when the patient has had a kidney transplant, and Ensacove is not covered after prior treatment with an ALK inhibitor. Epclusa Preferred must not be used with another HCV direct-acting antiviral agent.

    Evrysdi is not covered with concomitant chronic SMN-modifying therapy for SMA, such as Spinraza. Fabrazyme must not be used in combination with other drugs used for Fabry disease.

    Aimovig: Episodic migraine with >=4 migraine days/month or chronic migraine with >=8 migraine days/month and medication-overuse headache addressed; age >=18.
    Akeega: Metastatic BRCA-mutated prostate cancer used with prednisone and GnRH therapy.
    Alecensa: NSCLC.
    Prolastin-c: Congenital AAT deficiency with emphysema, conventional treatment, qualifying genotype, and serum AAT <11 µM/L.

    Initial Therapy Criteria

    Initial therapy requires the applicable product pathway.

    Avtozma: RA, GCA, SJIA, PJIA, or SSc-ILD meeting the indication-specific criteria and specialist requirements.
    Braftovi: Metastatic BRAF V600E-mutant NSCLC confirmed by approved testing and used with Mektovi.
    Bronchitol: Cystic fibrosis, passed Bronchitol Tolerance Test, and specialist involvement.
    Cablivi: aTTP, provider-administered IV bolus first dose, immunosuppressive therapy, and plasma-exchange requirement.
    Cabometyx: RCC, HCC, DTC, or previously treated unresectable/locally advanced/metastatic well-differentiated pNET/epNET with the applicable disease criteria.
    Caplyta: Schizophrenia, bipolar depression, or adjunctive MDD pathway with required generic-antipsychotic step therapy.
    Cayston: Evidence of Pseudomonas aeruginosa in the lungs; CF patients must be at least 7 years old.

    Initial Therapy Criteria

    Initial therapy requires one applicable diagnosis-specific pathway.

    Cerdelga: Gaucher disease type 1, age >=18, qualifying CYP2D6 metabolizer status.
    Chenodal: Radiolucent gallstones, well-opacifying gallbladder, nonsurgical candidacy, ursodiol failure/intolerance, and noncalcified stones.
    Cholbam: Qualifying single-enzyme bile-acid synthesis disorder or peroxisomal disorder with required clinical findings.
    Cialis/Ciclopirox/Cinryze: Meet the documented prerequisite, diagnostic, safety, age, and duplicate-therapy restrictions for the requested product.
    Cobenfy/Cometriq/Copiktra: Meet the applicable intolerance, metastatic MTC, or relapsed/refractory CLL/SLL with at least two prior therapies pathway.
    Cosentyx/Cosentyx IV: Meet the applicable inflammatory-disease diagnosis, severity, prior topical/NSAID/alternative therapy, and specialist criteria.
    Cotellic/Cresemba/Ctexli: Meet the applicable BRAF-mutated melanoma/histiocytic neoplasm, invasive fungal infection, or genetically confirmed CTX pathway.
    Cyclobenzaprine/Roflumilast/Danziten/Pyrimethamine: Meet the specified muscle-spasm/fibromyalgia/TMD, COPD with two prior therapies, Ph+ CML, or toxoplasmosis pathway; malaria is excluded.
    Daurismo: Newly diagnosed AML, low-dose cytarabine combination, and age >=75 or qualifying comorbidities.
    Deferasirox: Transfusional iron overload, qualifying MDS, or NTDT pathway with applicable ferritin, transfusion, and LIC thresholds.
    Metyrosine: Qualifying preoperative pheochromocytoma preparation or hormonally active pheochromocytoma treatment after required adrenergic blockade.

    Initial Therapy Criteria

    Initial therapy requires the applicable disease and treatment pathway.

    Emgality through Fotivda: Meet the documented indication-specific criteria for migraine/cluster headache, renal complement disease, inflammatory disease, sickle cell disease, ALK-positive NSCLC, hepatitis C, qualifying seizure disorder, BCC, SMA, Fabry disease, eosinophilic disorders, cancer pain, HAE, LEMS, advanced prostate cancer, or advanced RCC.

    Initial Therapy Criteria

    Initial therapy requires the applicable diagnosis-specific criteria.

    Glycopyrrolate: Peptic ulcer and PPI or PPI-intolerance/H2-antagonist pathway.
    Gomekli: NF1 with inoperable plexiform neurofibromas.
    Preferred growth hormone products: Applicable diagnosis-specific pediatric or adult growth-hormone criteria and specialist involvement.
    Hernexeos/Hyrnuo: Qualifying HER2-mutated unresectable, locally advanced, or metastatic non-squamous NSCLC; Hyrnuo also requires prior systemic therapy.
    Humira: Applicable RA, PJIA, PsA, psoriasis, AS, Crohn disease, uveitis, UC, or HS criteria and required prior therapy.
    Inbrija: Parkinson disease with OFF episodes, carbidopa/levodopa, two adjunctive therapy failures/intolerances, and neurologist involvement.
    Increlex: Severe primary IGF-1 deficiency pathway or GH gene deletion with neutralizing antibodies; endocrinologist involvement.

    Continuation Criteria

    Reauthorization requires continuation of prior therapy or the applicable response measure.

    Continuation of prior therapy: Continuation may be approved for Briviact, Brukinsa, Cabometyx, Calquence, Caplyta, Caprelsa, Cobenfy, Cometriq, Cotellic, and other listed products when the existing treatment meets policy requirements.
    Bronchitol/Cayston: Positive clinical response or benefit; Cayston benefit may include fewer pulmonary exacerbations.
    Cholbam: Positive clinical response shown by improved liver function.
    Cinryze: Positive clinical response and no combination with another HAE prophylaxis.
    Cosentyx/Cosentyx IV: Positive response from baseline shown by indication-specific joint, symptom, BSA, laboratory, function, axial, or HS measures.
    Ctexli/Roflumilast/Metyrosine: Positive clinical response; for metyrosine, decreased frequency and severity of symptoms.
    Deferasirox: Reduction in ferritin or LIC for transfusional overload/MDS, or NTDT LIC at least 3 mg Fe/g dry weight with applicable additional criteria.

    Continuation Criteria

    Reauthorization requires continued eligibility and the applicable response or continuation criteria.

    Emgality: Positive response; decreased acute-migraine medication use for migraine; continued medication-overuse monitoring when applicable; and no prohibited CGRP combination.
    Empaveli: Positive response; for primary IC-MPGN, no kidney transplant and continued maximally tolerated ACE inhibitor, ARB, or SGLT2 therapy.
    Enbrel/Humira: Positive indication-specific response in joints, symptoms, BSA, disease activity, laboratory values, function, axial status, ocular disease, intestinal inflammation, or HS findings.
    Endari/Fasenra/Firdapse/Icatibant: Positive clinical response; icatibant must not be combined with another acute HAE treatment.
    Evrysdi: Positive response, no chronic SMN-modifying combination, and applicable prior gene-therapy requirement.
    Fabrazyme: Positive clinical response and no combination with another Fabry disease drug.
    Glycopyrrolate: Persistent or new peptic ulcer, continued acid-suppression pathway, and reduced symptoms.
    Preferred growth hormone products: Diagnosis-specific reauthorization evidence, including expected adult-height goal, positive response where required, or recent IGF-1 monitoring.
    Other listed products: Continuation of prior therapy may be approved for Ensacove, Epidiolex, Erivedge, Firmagon, Fotivda, Fintepla, and the listed oncology products when policy requirements continue to be met.
    Inbrija/Increlex: Positive clinical response to therapy.
    Product or indicationRequired prior therapyDuration or qualifying conditions
    Copiktra — CLL/SLLAt least two prior CLL/SLL therapies.Trial and failure, contraindication, or intolerance to at least two therapies; examples include chlorambucil, obinutuzumab, ofatumumab, bendamustine, ibrutinib, and rituximab.
    Cosentyx — plaque psoriasisOne qualifying topical therapy: corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor.At least a 4-week trial with failure, contraindication, or intolerance.
    Cosentyx — ankylosing spondylitisOne NSAID at the maximally tolerated dose.At least a 1-month trial with failure, contraindication, or intolerance.
    Cosentyx — nr-axSpA or ERATwo NSAIDs at maximally tolerated doses.At least a 1-month trial with failure, contraindication, or intolerance to both NSAIDs.
    Cosentyx IV — PsA, AS, or nr-axSpAFor PsA or AS, two listed alternatives; for nr-axSpA, both Cosentyx SC and Rinvoq.Trial and failure, contraindication, or intolerance to the required alternatives, unless requesting continuation of prior therapy.
    Roflumilast — COPDTwo prior COPD therapies.Trial and failure, intolerance, or contraindication to two therapies.
    Pyrimethamine — primary toxoplasmosis prophylaxisTMP-SMX prophylaxis.Prior TMP-SMX intolerance plus failed TMP-SMX desensitization or a prior life-threatening TMP-SMX reaction.
    Metyrosine — preoperative pheochromocytoma preparationBoth an alpha-adrenergic blocker and a beta-adrenergic blocker.Trial and failure, contraindication, or intolerance to both blocker classes.
    Metyrosine — pheochromocytoma treatmentSelective alpha-1-adrenergic blocker and beta-adrenergic blocker.The patient received both blockers but has not reached normotension.
    Metyrosine — blocker historyBoth an alpha-adrenergic blocker and a beta-adrenergic blocker.Use or attempted use of both classes; preoperative preparation requires failure, contraindication, or intolerance, while treatment requires failure to reach normotension.
    Product or indicationRequired prior therapyDuration or qualifying conditions
    Empaveli — C3G or primary IC-MPGNMaximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor.Therapy must be used for at least 12 weeks before Empaveli initiation; it must continue for reauthorization. Primary IC-MPGN is not covered after kidney transplant.
    Enbrel — rheumatoid arthritisMethotrexate, leflunomide, or sulfasalazine at maximally tolerated doses.Minimum 3-month trial with failure, contraindication, or intolerance.
    Enbrel — polyarticular juvenile idiopathic arthritisLeflunomide or methotrexate at maximally tolerated doses.Minimum 6-week trial with failure, contraindication, or intolerance.
    Enbrel — plaque psoriasisTopical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor.Minimum 30-day supply; topical corticosteroids may require 14 days. Failure, contraindication, or intolerance is required.
    Enbrel — ankylosing spondylitisOne NSAID at a maximally tolerated dose.Minimum 1-month trial with failure, contraindication, or intolerance.
    Epidiolex — Lennox-Gastaut syndromeTwo formulary anticonvulsants, such as topiramate, lamotrigine, or valproate.Trial, contraindication, or intolerance to two anticonvulsants is required.
    Epidiolex — seizure indicationsTwo formulary anticonvulsants for Lennox-Gastaut syndrome.The prerequisite applies to Lennox-Gastaut syndrome; it is not stated for Dravet syndrome or tuberous sclerosis complex.
    Eucrisa — mild to moderate atopic dermatitisOne prescription-strength topical corticosteroid, such as triamcinolone acetonide or fluocinolone acetonide.Trial and failure, contraindication, or intolerance, unless the affected area is sensitive, including the face, axillae, or groin.
    Fasenra — severe eosinophilic asthmaMedium-dose or high-dose inhaled corticosteroid regimen with an additional controller, or the applicable ICS/LABA regimen.Required controller therapy may be omitted when contraindicated or not tolerated; age-specific regimens apply.
    Fasenra — HESCorticosteroid therapy or cytotoxic/immunosuppressive therapy, such as hydroxyurea, cyclosporine, or imatinib.Trial and failure, contraindication, or intolerance is required.
    GlycopyrrolateConcomitant PPI therapy; if PPIs are contraindicated or not tolerated, an H2-receptor antagonist.The alternative pathway requires documented PPI contraindication or intolerance plus concomitant H2-receptor antagonist therapy.
    Humira — rheumatoid arthritisMethotrexate, leflunomide, or sulfasalazine.At least a 3-month trial with failure, contraindication, or intolerance at maximally tolerated doses.
    Humira — polyarticular juvenile idiopathic arthritisLeflunomide or methotrexate.At least a 6-week trial with failure, contraindication, or intolerance at maximally tolerated doses.
    Humira — plaque psoriasisTopical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor.Minimum 30-day trial; topical corticosteroids may require 14 days. Failure, contraindication, or intolerance is required.
    Humira — ankylosing spondylitisOne NSAID at a maximally tolerated dose.At least a 1-month trial with failure, contraindication, or intolerance.
    HyrnuoPrior systemic therapy, such as chemotherapy.Required for locally advanced or metastatic non-squamous NSCLC with an activating HER2/ERBB2 mutation.
    Hyrnuo — prior systemic therapyPrior systemic therapy, such as chemotherapy.Prior therapy must be documented along with the qualifying NSCLC diagnosis and HER2/ERBB2 mutation.
    IgalmiAt least two products used for acute agitation, such as olanzapine or ziprasidone.Trial and failure, contraindication, or intolerance to at least two products; maintenance medication for the underlying disorder is also required.
    Imbruvica — cGVHDOne or more lines of systemic therapy, such as corticosteroids including prednisone.Trial and failure of one or more systemic therapy lines is required.
    InbrijaTwo adjunctive therapy classes: MAO-B inhibitor, dopamine agonist, or COMT inhibitor.Trial and failure, contraindication, or intolerance to two classes is required.
    Two prior COPD therapies
    Daurismo age criterionAt least 75 years when age is the qualifying condition
    Treatment duration and laboratory thresholds
    Sickle cell crisesAt least 2 painful sickle cell crises within the past 12 months
    Empaveli prerequisite therapyMaximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor therapy for at least 12 weeks before initiation
    Enbrel rheumatoid arthritis trialMinimum 3-month trial of conventional therapy
    Enbrel PJIA trialMinimum 6-week trial of conventional therapy
    Enbrel plaque psoriasis trialMinimum 30-day supply of topical therapy, or 14-day supply for topical corticosteroids
    Enbrel ankylosing spondylitis trialMinimum 1-month trial of one NSAID
    Procrit anemia laboratory thresholdFor chronic kidney disease or chemotherapy anemia: Hct less than 30% or Hgb less than 10 g/dL
    Diagnostic and treatment thresholds
    Severe eosinophilic asthmaBaseline pretreatment eosinophils at least 150 cells per microliter
    Hypereosinophilic syndromePretreatment eosinophils at least 1,000 cells per microliter
    Opioid toleranceAt least 1 week at the qualifying dose: morphine ≥60 mg/day; transdermal fentanyl ≥25 micrograms/hour; oxycodone ≥30 mg/day; oral hydromorphone ≥8 mg/day; oral oxymorphone ≥25 mg/day; oral hydrocodone ≥60 mg/day; or oral methadone ≥20 mg/day
    Pediatric growth hormone deficiency heightMore than 2.0 SD below midparental height or more than 2.25 SD below the population mean; below the 1.2 percentile
    Pediatric growth hormone deficiency growth velocityMore than 2 SD below the mean for age and gender
    Adult GH stimulation testingPeak GH at or below 5 mcg/L for insulin tolerance testing, at or below 3 mcg/L for glucagon, or at or below 2.8 ng/mL for macimorelin
    Increlex diagnostic thresholdsHeight standard deviation score and basal IGF-1 standard deviation score both -3.0 or less
    Enbrel: 6 months initial and 12 months reauthorization; Epclusa Preferred: 12 to 24 weeks; Glycopyrrolate: 3 months initial and reauthorization; Humira: 12 weeks initial for ulcerative colitis, 6 months initial for other indications, and 12 months for reauthorization
  1. Akeega: document metastatic prostate cancer with deleterious or suspected deleterious BRCA mutation, use with prednisone and a GnRH agent, and continuation status.
  2. Alecensa: document NSCLC diagnosis and continuation of prior therapy.
  3. Prolastin-c: document congenital AAT deficiency with emphysema, continued conventional emphysema treatment, qualifying genotype, and pretreatment serum AAT below 11 µM/L (or corresponding assay threshold); document positive response and continued emphysema treatment for reauthorization.
  4. Prior Authorization

    Braftovi Through Cayston: Authorization and Documentation

    Submit indication-specific clinical records and prior-treatment documentation for authorization of Braftovi through Cayston. Coverage generally requires continuation documentation and, where specified, a qualified specialist or disease-specific combination regimen.

    • Braftovi: document approved melanoma, colorectal cancer, or metastatic BRAF V600E-mutant NSCLC indication, required BRAF testing, and required combinations such as Erbitux, Mektovi, or fluorouracil-based chemotherapy; prior therapy may be required for colorectal cancer.
    • Briviact: document partial-onset seizures and patient age at least 1 month.
    • Bronchitol: document cystic fibrosis, a passed Bronchitol Tolerance Test, pulmonologist/specialist involvement, and positive response for reauthorization.
    • Brukinsa: document MCL with at least one prior therapy, WM/LPL, relapsed/refractory MZL with prior anti-CD20 therapy, CLL/SLL with Calquence contraindication or intolerance, or relapsed/refractory FL with required Gazyva combination and at least two prior systemic lines.
    • Cablivi: document acquired TTP, immunosuppressive therapy, plasma exchange or qualifying post-plasma-exchange timing, hematologist/oncologist involvement, and first-dose administration by a healthcare provider as a bolus IV injection.
    • Cabometyx: document RCC, HCC with Nexavar failure/intolerance, DTC progressed after VEGFR therapy and radioactive-iodine refractory/ineligible status, or well-differentiated unresectable/locally advanced/metastatic NET with prior treatment.
    • Calquence: document MCL with the applicable transplant/prior-therapy pathway or CLL/SLL criteria, including required combination therapy when applicable.
    • Caplyta: document schizophrenia, bipolar depression, or adjunctive MDD indication and failure, contraindication, or intolerance to the required formulary atypical antipsychotics.
    • Caprelsa: document symptomatic or progressive metastatic or unresectable locally advanced medullary thyroid cancer.
    • Cayston: document cystic fibrosis and evidence of Pseudomonas aeruginosa in the lungs; initial therapy requires age 7 or older and reauthorization requires clinical benefit, such as fewer pulmonary exacerbations.
    Documentation Required

    Cerdelga Through Metyrosine: Disease, Diagnostic, and Prerequisite Criteria

    For Cerdelga through Metyrosine, provide the disease-specific diagnosis, diagnostic testing, laboratory evidence, treatment history, safety information, and specialist records required by the indication. Missing evidence or failure to satisfy prerequisite therapy creates a denial risk.

    • Cerdelga: document type 1 Gaucher disease, age 18 or older, and CYP2D6 extensive, intermediate, or poor metabolizer status from an FDA-cleared test.
    • Chenodal: document suitable radiolucent gallstones, a well-opacifying gallbladder, nonsurgical candidacy, noncalcified stones, unsuccessful/intolerant ursodiol therapy, and gastroenterologist involvement; reauthorization requires imaging reassessment.
    • Cholbam: document bile-acid synthesis disorder or peroxisomal disorder by urinary bile-acid mass spectrometry or molecular testing, applicable clinical manifestations, adjunctive use, and specialist prescribing; show improved liver function for reauthorization.
    • Cialis: document no concurrent nitrate use and contraindication, intolerance, or failure of an alpha-blocker or 5-alpha-reductase inhibitor when required.
    • Ciclopirox: document confirmed onychomycosis without matrix involvement, disease severity/site, and required oral terbinafine trial or contraindication/intolerance.
    • Cinryze: document confirmed HAE by complement/C1-INH testing or qualifying genetic/family-history evidence, age at least 6, allergist/immunologist involvement, and no concurrent prophylactic HAE therapy; show positive response at reauthorization.
    • Cobenfy: document the covered psychiatric indication and failure, contraindication, or intolerance to two formulary oral atypical antipsychotics; continuation of prior therapy must be supported.
    • Cometriq: document metastatic medullary thyroid cancer and continuation status.
    • Copiktra: document relapsed/refractory CLL or SLL and failure, contraindication, or intolerance to at least two prior therapies.
    • Ctexli: document cerebrotendinous xanthomatosis, pathogenic CYP27A1 variant confirmation, and neurologist, geneticist, metabolic specialist, or endocrinologist involvement; show positive response for reauthorization.
    • Cyclobenzaprine: document acute painful muscle spasm, qualifying fibromyalgia symptoms, or acute temporomandibular disorder with required NSAID combination; acknowledge anticholinergic risk, and note the age-65-or-older PA restriction.
    • Roflumilast: document COPD, qualifying exacerbations requiring systemic steroids/antibiotics/hospitalization, failure/intolerance/contraindication to two prior COPD therapies, and positive response for reauthorization.
    • Danziten: document Philadelphia chromosome-positive CML and continuation status.
    • Pyrimethamine: restrict coverage to qualifying active, congenital, secondary-prophylaxis, or specially documented primary-prophylaxis toxoplasmosis; document TMP-SMX intolerance/desensitization failure where required. Malaria treatment or prophylaxis is not authorized.
    • Daurismo: document newly diagnosed AML, low-dose cytarabine combination, and age at least 75 or comorbidities precluding intensive therapy.
    • Deferasirox: document transfusional iron overload with ferritin/transfusion thresholds, qualifying MDS, or NTDT with liver iron and ferritin thresholds, plus required age and reauthorization laboratory response.
    • Metyrosine: document biochemically confirmed pheochromocytoma, the preoperative or treatment indication, specialist involvement, and required alpha- and beta-adrenergic blockade.
    Prior Authorization

    Emgality Through Fotivda: Clinical Authorization and Response Evidence

    For Emgality through Fotivda, authorization depends on documented clinical eligibility, disease confirmation, specialist involvement when required, laboratory or biomarker evidence, prerequisite treatment, and measurable response for continuation.

    • Emgality: document episodic migraine, chronic migraine, or episodic cluster headache using the required frequency/history thresholds; document age, medication-overuse assessment, and no prohibited CGRP combination. Reauthorization requires positive response and reduced acute migraine medication use where applicable.
    • Empaveli: document PNH, C3G, or primary IC-MPGN; for IC-MPGN document no kidney transplant, proteinuria reduction goal, age at least 12, and at least 12 weeks of maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor therapy. Show positive response and continued prerequisite therapy.
    • Enbrel: document the covered inflammatory indication, disease activity/severity, required conventional or biologic treatment history, specialist involvement, and positive response for renewal.
    • Endari: document sickle cell disease and at least two painful crises in the prior 12 months; provide response evidence for continuation.
    • Ensacove: document locally advanced or metastatic ALK-rearrangement-positive NSCLC by an FDA-approved or CLIA test and no prior ALK inhibitor.
    • Epclusa Preferred: document chronic hepatitis C under current AASLD/IDSA guidance, regimen appropriateness, no duplicate HCV direct-acting antiviral, and required hepatology, gastroenterology, infectious-disease, HIV, or liver-transplant specialist involvement unless exempt.
    • Epidiolex: document seizures associated with LGS, Dravet syndrome, or TSC; patient must be at least 1 year old, have neurologist involvement, and have tried, been intolerant of, or had a contraindication to two formulary anticonvulsants.
    • Procrit: submit diagnosis-specific clinical and laboratory records, including hemoglobin/hematocrit, CKD, chemotherapy, HCV/ribavirin, HIV, MDS, or preoperative criteria; document adequate iron stores and response. Requests may be denied when hemoglobin/hematocrit exceeds applicable limits.
    • Evrysdi: document SMA type I, II, or III, SMN1/5q findings, at least two SMN2 copies, baseline motor assessment, respiratory eligibility, and no concomitant chronic SMN-modifying therapy. Document prior gene therapy and inadequate response when applicable; reauthorization requires positive response.
    • Fabrazyme: document Fabry disease by GLA mutation, deficient alpha-galactosidase A activity, or significant clinical manifestations; provide diagnostic evidence and response. Do not combine with another Fabry-specific therapy.
    • Fasenra: document severe eosinophilic asthma with qualifying eosinophil count, exacerbations/hospitalization, controller therapy, and pulmonologist/allergist involvement; for EGPA or HES provide disease workup, exclusions, eosinophil results, prior corticosteroid/immunosuppressive therapy, and specialist records.
    • Fentanyl transmucosal: document breakthrough cancer pain, around-the-clock long-acting opioid therapy, at least one week of opioid tolerance at the required dose or equianalgesic dose, and pain/oncology/hospice/palliative specialist involvement.
    • Fintepla: document Dravet or Lennox-Gastaut syndrome seizures, age at least 2, neurologist involvement, and continuation status.
    • Icatibant: document acute HAE attack treatment, confirmed HAE by complement/C1-INH or qualifying genetic/family-history evidence, age at least 18, specialist involvement, and no duplicate acute HAE therapy.
    • Firdapse: document LEMS, age at least 6, neurologist involvement, and positive response for renewal.
    • Firmagon: document advanced or metastatic prostate cancer.
    • Fotivda: document advanced relapsed/refractory RCC and at least two prior systemic therapies.

    Unsupported block type: documentation

    Denial Risk

    Common Denial Risks and Unmet Criteria

    Denial risk is high when the requested product is used for an unapproved or excluded indication, required diagnostic or biomarker evidence is absent, prerequisite therapy is not documented, age or specialist requirements are unmet, or continuation response is not demonstrated.

    • Alyq/Adempas: deny when PAH or CTEPH criteria, symptomatic disease, confirmatory testing/current therapy, specialist involvement, or positive response is absent.
    • Afinitor/Afinitor Disperz/Aimovig/Akeega/Alecensa/Prolastin-c: deny when the diagnosis, prerequisite or combination therapy, age, genetic/serum evidence, or continuation response is not established; Aimovig cannot be combined with another preventive CGRP inhibitor.
    • Braftovi through Cayston: deny for missing BRAF/ALK or disease evidence, absent required combinations or prior therapies, missing CF/Pseudomonas evidence, failed Bronchitol Tolerance Test, age restriction, or lack of Cayston clinical benefit.
    • Cerdelga through Metyrosine: deny for absent pharmacogenetic or diagnostic confirmation, unsuitable gallstone disease, nitrate use, failure to try ursodiol/terbinafine/required atypical antipsychotics or oncology therapies, unqualified indication, malaria use of pyrimethamine, essential-hypertension use of metyrosine, or missing adrenergic blockade.
    • Cosentyx and related inflammatory products: deny when plaque psoriasis topical therapy, AS NSAID trial, nr-axSpA/ERA NSAID trials, or required IV alternative therapy is not documented; positive response must be shown for reauthorization.
    • Cresemba: deny when invasive aspergillosis or mucormycosis is not documented.
    • Ctexli: deny without cerebrotendinous xanthomatosis and CYP27A1 confirmation or required specialist involvement.
    • Emgality through Fotivda: deny when migraine, seizure, HAE, LEMS, cancer, asthma, HES/EGPA, HCV, SMA, Fabry, or RCC criteria are not met; deny for absent biomarker/laboratory evidence, prerequisite therapy, opioid tolerance, or continuation response.
    • Glycopyrrolate through Increlex: deny for absent peptic-ulcer/PPI or H2 pathway, NF1 disease, growth-hormone diagnostic evidence, HER2/ROS1/IDH2 molecular eligibility, psychiatric acute-agitation criteria, swallow/formulation requirement, Parkinson adjunctive therapy, or IGF-1/GH criteria.
    • General exclusions: malaria use, essential hypertension treatment with metyrosine, duplicate Fabry therapy, duplicate acute or prophylactic HAE therapy, duplicate preventive CGRP therapy, and prohibited concomitant SMA-modifying therapy are not covered. Requests lacking required medical information, clinical criteria, prerequisite therapy, age eligibility, specialist qualification, or positive response are at risk for denial.
    Step Therapy

    Step Therapy and Prerequisite Part D Documentation

    Many products require indication-specific prerequisite Part D therapy or step therapy before initial approval. Document drug name, dose and duration when available, treatment failure, contraindication, intolerance, or why a trial is inappropriate.

    • Rheumatology/dermatology: document conventional RA/PJIA therapy; topical therapy for plaque psoriasis; NSAID trials for AS; two NSAID trials for nr-axSpA/ERA; and qualifying biologic or targeted-therapy trials for PsA, AS, or other inflammatory indications. Enbrel requires the applicable conventional-therapy or biologic prerequisite.
    • Caplyta/Cobenfy: document required trials, failure, contraindication, or intolerance to formulary atypical antipsychotics; Cobenfy requires two oral generic atypical antipsychotic agents.
    • Chenodal/Cialis/Ciclopirox: document ursodiol, alpha-blocker or 5-alpha-reductase inhibitor, and oral terbinafine prerequisites, respectively.
    • Copiktra/Brukinsa/Cabometyx/Calquence: document the required prior oncology therapies, disease relapse/refractoriness, contraindications, or intolerance.
    • Cosentyx: document topical plaque-psoriasis therapy, an NSAID trial for AS, two NSAID trials for nr-axSpA/ERA, and required alternative therapy before IV use.
    • Empaveli: document at least 12 weeks of maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor therapy for C3G/primary IC-MPGN.
    • Epidiolex: document trials of two formulary anticonvulsants.
    • Fasenra: document required asthma controller therapy and prior corticosteroid or cytotoxic/immunosuppressive therapy for HES.
    • Humira/Enbrel: document required conventional DMARD, topical, NSAID, or biologic therapy by indication.
    • Igalmi: document failure, contraindication, or intolerance to at least two products used for acute agitation and maintenance therapy for the underlying disorder.
    • Imbruvica: document prior systemic therapy for cGVHD.
    • Inbrija: document current carbidopa/levodopa and failure, contraindication, or intolerance to two adjunctive treatment classes.
    • Other prerequisite pathways: provide clinical and prerequisite documentation whenever the request indicates required Part D therapy; absence of that documentation may result in denial.
    Billing Rule

    Cablivi Site-of-Care Requirement

    For Cablivi, the first dose must be administered by a healthcare provider as a bolus intravenous injection. Include administration records or a plan confirming compliance with this site-of-care requirement.

    • Document acquired TTP diagnosis, immunosuppressive therapy, and concurrent plasma exchange or qualifying post-plasma-exchange timing.
    • Use a hematologist or oncologist, or document consultation with one.
    • The initial dose may not be self-administered; provider administration is required.
    SSc-ILD: systemic sclerosis-associated interstitial lung disease; the idiopathic interstitial pneumonia pattern may include fibrotic nonspecific interstitial pneumonia, usual interstitial pneumonia, or centrilobular fibrosis
    Disease and treatment definitions
    SMA eligibilitySpinal muscular atrophy type I, II, or III with chromosome 5q-related SMN1 mutation or deletion and at least two copies of SMN2
    Evrysdi baseline motor assessmentBaseline motor ability may be established using HINE-2, HFMSE, RULM, CHOP INTEND, MFM-32, or Item 22 of the BSID-III, selected according to age and motor ability
    Eosinophilic asthma, EGPA, and HESEosinophilic asthma: severe asthma with baseline pretreatment eosinophils of at least 150 cells per microliter; EGPA: eosinophilic granulomatosis with polyangiitis; HES: hypereosinophilic syndrome
    Breakthrough cancer painPain occurring despite ongoing around-the-clock long-acting opioid treatment for cancer pain
    HAE and HAE-nl-C1INHHAE: hereditary angioedema; HAE-nl-C1INH: hereditary angioedema with normal C1 inhibitor levels, previously referred to as type III HAE
    LEMSLambert-Eaton myasthenic syndrome
    HER2-mutated and ROS1 rearrangement-positive NSCLC; OFF episodesHER2-mutated NSCLC: locally advanced or metastatic non-squamous NSCLC with an activating HER2 tyrosine kinase domain mutation; ROS1 rearrangement-positive NSCLC: NSCLC with a ROS1 rearrangement-positive tumor confirmed by an FDA-approved or CLIA-approved test; OFF episodes: periods when Parkinson disease symptoms return or worsen despite ongoing levodopa treatment